Avacopan

(Tavneos®)

Tavneos®

Drug updated on 5/17/2024

Dosage FormCapsule (oral; 10 mg)
Drug ClassComplement 5a receptor antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Avacopan (Tavneos) is indicated as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis in combination with standard therapy including glucocorticoids. It is part of the emerging treatments aimed at minimizing the adverse effects of conventional therapies such as glucocorticoids, which are associated with numerous harmful effects.
  • Two systematic reviews/meta-analyses were analyzed to gather information about Tavneos and its application in treating ANCA-associated vasculitis.
  • When compared to other drugs such as Rituximab, Cyclophosphamide, Mycophenolate Mofetil, and Plasma Exchange used for treating ANCA-associated vasculitis, avacopan has shown potential benefits; however, detailed comparative data on safety and effectiveness were not directly available from the reviewed studies.
  • Rituximab provides a safer alternative to glucocorticoids while exhibiting equal or superior effectiveness. This suggests significant benefits, particularly for those at risk from the adverse effects of glucocorticoids.
  • The geriatric population is emphasized due to their higher risk of adverse effects from traditional therapies because ANCA-associated vasculitis is more commonly seen in this demographic group.
  • Renal vasculitis conditions presenting as rapidly progressive glomerulonephritis suggest a subgroup within the ANCA-associated vasculitis spectrum requiring specific treatment considerations, especially when managing severe acute kidney injury cases.